Navigation Links
ParagonRx Files with FDA REMS Panel Interim Analysis for Opioid Drugs Study
Date:7/15/2009

WILMINGTON, Del., July 15 /PRNewswire/ -- ParagonRx, a healthcare consulting leader in risk management and the appropriate use of drugs, has filed its interim analysis of a study that shows how its proprietary approach to risk management can help manufacturers of opioid drugs meet FDA standards for risk evaluation and mitigation strategy (REMS.) ParagonRx had presented abbreviated study results to the FDA during public hearings earlier this year.

The interim analysis can be accessed at ParagonRx's website, www.paragonrx.com/experience/comments-to-the-fda/

"ParagonRx has developed a proprietary approach to risk management using an adaptation of failure modes and effect analysis called RxFMEA(R)," says Jeffrey Fetterman, President and CEO of ParagonRx, "and we are currently applying this approach to the medication use process for long-acting opioids. RxFMEA(R) provides a rigorous assessment to identify key causes of sub-optimal outcomes and to prioritize those behaviors that are the most important to address."

ParagonRx is a Delaware-based company that works with pharmaceutical, biotech and medical devices companies to design and implement REMS and other risk management plans as well as better market under-utilized drugs.


'/>"/>
SOURCE ParagonRx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ParagonRx Creates New Website Featuring REMS Help Center for Pharma
2. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
3. OncoGenex Pharmaceuticals Files Shelf Registration Statement
4. CEL-SCI Files Patent Application to Support Companys Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
5. Pharmacyclics Files Registration Statement for Rights Offering
6. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
7. Poniard Pharmaceuticals Files Shelf Registration
8. Sinovac Biotech Ltd. Files Annual Report on Form 20-F
9. SPO Medical Files Annual Report for Fiscal 2008
10. Vermillion, Inc. Files a Voluntary Petition for Reorganization Relief Under Chapter 11 of the United States Bankruptcy Code
11. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... England , December 8, 2016 ... das Unternehmen für Molekulargenetik, erweitert seine Palette an ... myPanel™ NGS Custom FH Panels, das ein schnelles ... (FH) ermöglicht. Das Panel bietet eine Erkennung von ... Variations (CNV) mit einem einzigen kleinen Panel und ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... commercial launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal ... extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture ...
(Date:12/8/2016)... Dec. 8, 2016 Soligenix, Inc. (OTCQB: SNGX) ... on developing and commercializing products to treat rare diseases ... that it will be hosting an Investor Webcast Event ... the origins of innate defense regulators (IDRs) as a ... oral mucositis and the recently announced and published Phase ...
(Date:12/8/2016)... to fuel Philadelphia,s innovative digital ... Southeastern Pennsylvania (" Ben Franklin "); Independence ... Cross; and Safeguard Scientifics ("Safeguard") (NYSE: SFE ... funding initiative over a four year period to grow ... burgeoning economic vitality in digital health, Ben Franklin ...
Breaking Biology Technology:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):